Journal of Liver

Dr. Raggi Chiara

Dr. Raggi Chiara
Liver Unit and Center Autoimmune Liver Diseases Humanitas Clinical and Research Center, Rozzano, Italy chiara.raggi@humanitasresearch.it.

Biography

Dr. Raggi Chiara has received her PhD in General pathology at the University of Pisa (Italy) in 2007. At the end of her PhD program, she joined as a post-doctoral fellow the Laboratory of Experimental Carcinogenesis (LEC) at the National Cancer Institute (NCI) - NIH (Bethesda, US) directed by Dr. S. S. Thorgeirsson to continue her studies on human carcinogenesis. During her fellowship at the LEC, Dr. Raggi has focused her activity on cancer stem cell (CSC) aspects of hepatocellularcarcinoma (HCC) . Within her research on the HCC-CSCs, Dr. Raggi has examined the role of epigenetic modifications on hepatic CSCs in addition to develop an in vitro model to analyze CSC-response to both cell microenvironment and DNMT1-machinery. Dr. Raggi’s investigations have been presented in several national and international meetings (AASLD Liver Meeting 2013-Washington DC; AISF 2014 meeting-Rome) and awarded by EASL-HCC summit (2014). She is also a member of the Editorial Board of World Journal of Hepatology and has reviewed several manuscripts for leading scientific journals (World J Gastroenterol, Digest Liver Dis, J Hepatol). Dr. Raggi also acted as reviewer of scientific projects for Italian MOH grants (Ricerca Finalizzata 2010). Since the end of 2012, she joined Dr. Invernizzi group at Humanitas Institute in Milan (Italy), as an independent research and she started to investigate CSC-biology in human cholangiocarcinoma (CCA) and cross-talk with macrophages.

Research Interest

Given her background in human cancer stem cell (CSC) and her expertise in primary liver tumors, Dr. Raggi’s scientific interests are manly focused on cholangiocarcinoma disease in the context of innate immunity. In particular she aims to investigate CSC-tumor associated macrophage dependent modulation in human cholangiocarcinoma.